ArticleFrontiers in oncology2026
Case Report: rectal perforation and Fournier's gangrene after irinotecan in a bevacizumab-exposed, previously irradiated patient.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab-associated intestinal perforation and Fournier's gangrene have been reported separately; however, the potential contribution of residual anti-VEGF exposure prior to subsequent chemotherapy in previously irradiated pelvic tissue remains underrecognized. Radiotherapy causes fibrosis and microvascular injury, bevacizumab impairs healing, and irinotecan-induced diarrhea may exacerbate perforation risk. Deferring DRE, imaging, and surgical consultation in patients with unexplained perineal or buttock pain increases the risk. A 61-year-old man with rectal adenocarcinoma received neoadjuvant chemoradiotherapy followed by total mesorectal excision and ileostomy in March 2024. After adjuvant chemotherapy, surveillance in March 2025 revealed recurrence with pelvic invasion and liver/lung metastases. He received eight cycles of XELOX plus bevacizumab, then bevacizumab maintenance, stopped on 4 March 2026 for rectal hemorrhage. This 22-day interval is shorter than the label-mandated 28-day hold and NCCN-recommended ≥6-week washout for surgery-standards primarily addressing wound healing rather than chemotherapy sequencing. Five days after irinotecan initiation, grade 3 diarrhea developed. He was admitted on 13 April 2026 with diarrhea, left buttock pain; he received empirical ceftazidime plus moxifloxacin. On 14 April, DRE, imaging, and surgical consultation were deferred due to pain. By 18 April, septic shock developed with perineal necrosis and crepitus. CT confirmed Fournier's gangrene. Emergency debridement with abscess curettage and seton drainage was performed. Fecal diversion was declined. Antibiotics were escalated to meropenem then vancomycin after cultures grew
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.